𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Choice of route of exposure in mammalian genotoxicity experiments

✍ Scribed by John Ashby


Publisher
John Wiley and Sons
Year
1987
Tongue
English
Weight
115 KB
Volume
10
Category
Article
ISSN
0893-6692

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Genotoxicity assessment of oxirane-based
✍ Kostoryz, Elisabet L. ;Wetmore, Lori A. ;Brockmann, William G. ;Yourtee, David M πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 109 KB

## Abstract The potential use of oxirane (epoxy) monomers in dental composite development raises the concern to test their genetic safety. Oxiranes can interact with DNA resulting in DNA damage, mutations, and possibly carcinogenesis. Our objective was to evaluate DNA damage and cell‐cycle disrupti

Appropriate levels of cytotoxicity for g
✍ Lutz MΓΌller; Toshio Sofuni πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 37 KB

Among standard battery genotoxicity assays, the in vitro chromosome aberration test and the mouse lymphoma tk assay (MLA) yield about fourfold higher incidences of positive test results than the bacterial reverse mutation test or in vivo bone marrow tests. This is a result of experience with submiss

Ranking of Simultaneously Presented Choi
✍ Ulrich Halekoh; Erik JΓΈrgensen; Margit Bak Jensen; Lene Juul Pedersen; Merete St πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 140 KB

## Abstract We considered experiments where animals chose one of all possible simultaneously presented options. The animals might be observed at repeated occasions. In the ethological literature the analysis is often focused on testing the global hypothesis of no difference in preferences by non‐p

Absence of genotoxic effects after expos
✍ H. M. Rumpf; E. Dopp; A. W. Rettenmeier; M. Chatzinikolaidou; H. P. Jennissen πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 130 KB

## Abstract Recombinant human bone morphogenetic protein 2 (rhBMP‐2) has been widely employed for the induction of bone growth in animal models and in clinical trials. Since rhBMP‐2 is commercially available only to a very limited extent, we have prepared our own recombinant material for the curren